MA46563B1 - Compositions dispersibles - Google Patents

Compositions dispersibles

Info

Publication number
MA46563B1
MA46563B1 MA46563A MA46563A MA46563B1 MA 46563 B1 MA46563 B1 MA 46563B1 MA 46563 A MA46563 A MA 46563A MA 46563 A MA46563 A MA 46563A MA 46563 B1 MA46563 B1 MA 46563B1
Authority
MA
Morocco
Prior art keywords
compositions
dispersible compositions
useful
dispersible
rilpivirine
Prior art date
Application number
MA46563A
Other languages
English (en)
Other versions
MA46563A (fr
Inventor
Harshad Patankar
Nicolaas Martha Felix Goyvaerts
Rajan Gopal Rajan Ranga
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA46563A publication Critical patent/MA46563A/fr
Publication of MA46563B1 publication Critical patent/MA46563B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des compositions dispersibles comprenant de la rilpivirine ou un sel d'addition d'acide pharmaceutiquement acceptable de celle-ci en tant que principe actif. Ces compositions s'avèrent utiles dans le traitement d'une infection par le vih et leurs propriétés de dispersibilité les rend utiles en particulier auprès de la population pédiatrique ou gériatrique.
MA46563A 2016-10-24 2017-10-23 Compositions dispersibles MA46563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (fr) 2016-10-24 2017-10-23 Compositions dispersibles

Publications (2)

Publication Number Publication Date
MA46563A MA46563A (fr) 2019-08-28
MA46563B1 true MA46563B1 (fr) 2024-01-31

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46563A MA46563B1 (fr) 2016-10-24 2017-10-23 Compositions dispersibles

Country Status (21)

Country Link
US (2) US11065198B2 (fr)
EP (2) EP4248947A3 (fr)
JP (2) JP7197474B2 (fr)
KR (2) KR20190073450A (fr)
CN (1) CN110191704A (fr)
CA (1) CA3039562A1 (fr)
DK (1) DK3528791T3 (fr)
ES (1) ES2970870T3 (fr)
FI (1) FI3528791T3 (fr)
HR (1) HRP20240118T1 (fr)
HU (1) HUE064823T2 (fr)
LT (1) LT3528791T (fr)
MA (1) MA46563B1 (fr)
MX (1) MX2019004767A (fr)
PL (1) PL3528791T3 (fr)
PT (1) PT3528791T (fr)
RS (1) RS65159B1 (fr)
SI (1) SI3528791T1 (fr)
SM (1) SMT202400060T1 (fr)
TW (1) TWI821163B (fr)
WO (1) WO2018077815A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
EP4065121A4 (fr) 2019-11-29 2023-11-29 Aptorum Therapeutics Limited Composition comprenant de la rilpivirine et son utilisation pour le traitement de tumeurs ou du cancer
WO2021253380A1 (fr) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Formulations orales et leurs utilisations
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (fr) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Comprimés dispersibles enrobés par compression
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DK1529032T3 (da) 2002-08-09 2013-07-08 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill
AU2005279158C1 (en) * 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
BRPI0514871A (pt) * 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
CN101478950B (zh) 2006-06-23 2013-02-06 泰博特克药品有限公司 Tmc278的水性悬浮液
WO2015120014A1 (fr) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Nouveaux systèmes de désintégration de formes dosifiées pharmaceutiques
WO2015136294A1 (fr) * 2014-03-13 2015-09-17 Cipla Limited Composition pharmaceutique comprenant de la rilpivirine
EP3142640A1 (fr) * 2014-05-16 2017-03-22 Vivus, Inc. Forme dosifiée à désintégration par voie orale pour l'administration d'avanafil, et procédés associés de fabrication et d'utilisation

Also Published As

Publication number Publication date
JP2020500168A (ja) 2020-01-09
SI3528791T1 (sl) 2024-04-30
KR102861006B1 (ko) 2025-09-16
EP3528791B1 (fr) 2023-12-06
PL3528791T3 (pl) 2024-04-02
BR112019007564A2 (pt) 2019-07-02
RU2019115672A (ru) 2020-11-24
RU2019115672A3 (fr) 2021-01-21
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30
JP2023011659A (ja) 2023-01-24
PT3528791T (pt) 2024-02-19
SMT202400060T1 (it) 2024-03-13
TWI821163B (zh) 2023-11-11
HUE064823T2 (hu) 2024-04-28
ES2970870T3 (es) 2024-05-31
CA3039562A1 (fr) 2018-05-03
WO2018077815A1 (fr) 2018-05-03
MA46563A (fr) 2019-08-28
RS65159B1 (sr) 2024-02-29
HRP20240118T1 (hr) 2024-04-12
LT3528791T (lt) 2024-05-27
EP4248947A3 (fr) 2023-11-22
US20200069579A1 (en) 2020-03-05
JP7197474B2 (ja) 2022-12-27
KR20190073450A (ko) 2019-06-26
DK3528791T3 (da) 2024-01-29
EP4248947A2 (fr) 2023-09-27
EP3528791A1 (fr) 2019-08-28
TW201828927A (zh) 2018-08-16
MX2019004767A (es) 2019-07-01
US11065198B2 (en) 2021-07-20
CN110191704A (zh) 2019-08-30
US20220008333A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MA41411B1 (fr) Compositions dispersibles
MA46563B1 (fr) Compositions dispersibles
MA51530B1 (fr) Composés cycliques fondus
JOP20190193B1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA34002B1 (fr) Thérapie antivirale
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA39777A (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
MY186986A (en) Compositions and methods of use of phorbol esters
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
MA43960A (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
BR112020020708A8 (pt) Derivados da ureia cíclica fundidã como antagonista crhr2
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA53898B1 (fr) Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
WO2020044114A3 (fr) Composition pharmaceutique de méthotrexate